Biosimilar Guidances Could Be Left Out In Cold By White House Regulatory Freeze
Trump Administration memo could further delay some US FDA guidance documents already past due under the FDA Safety and Innovation Act; attorneys predict uncertainty about, but no immediate impact on, biosimilar and communications draft guidances released in last few weeks of the Obama Administration.
You may also be interested in...
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.
US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.